<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Promethazine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Promethazine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Promethazine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11842" href="/d/html/11842.html" rel="external">see "Promethazine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12735" href="/d/html/12735.html" rel="external">see "Promethazine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F58959169"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">Promethazine Injection Safety Update</span>
<span class="collapsible-date">December 2023</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">The FDA is alerting health care providers of labeling updates to further reduce the risk of severe chemical irritation and damage to tissues from IV administration of promethazine. The FDA recommends administration of promethazine by deep IM injection instead of IV administration. The FDA has required that manufacturers update the prescribing information to include new safety information and update the carton labeling and container labeling with the corresponding information.</p>
<p style="text-indent:0em;">If deep IM administration is NOT possible, promethazine:</p>
<ul>
<li>
<p style="text-indent:0em;">can be administered IV only after dilution, as recommended, and infused through an IV catheter inserted in a large vein and preferably through a central venous catheter. Do not administer using IV catheters placed into veins in the hand or wrist.</p></li>
<li>
<p style="text-indent:0em;">should NOT be mixed with other drugs or diluted with solutions other than 0.9% sodium chloride.</p></li>
<li>
<p style="text-indent:0em;">is contraindicated for IV administration at concentrations greater than 1 mg/mL.</p></li></ul>
<p style="text-indent:0em;">Further information may be found at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Ffda-requires-updates-labeling-promethazine-hydrochloride-injection-products&amp;token=p4xxQNnsmsxX5cY%2FoX7oZzW9UedxckXOekMjeNaOqpuBUd%2FFzwU3jLO68b2t%2F0h63nOqfaA64AYFAqyqvaq3fndUhaaGj%2F6Lge0mdiLn1ZgtWIFEAueCZyswFW%2FGOg9lTcQtEEnu%2BvdMuVfR3y%2FRPg%3D%3D&amp;TOPIC_ID=9820" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-updates-labeling-promethazine-hydrochloride-injection-products</a>.</p></div>
</div>
</div>
<div class="block black-box-warn drugH1Div" id="F5709344"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Respiratory depression - Pediatrics:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Promethazine should not be used in pediatric patients younger than 2 years because of the potential for fatal respiratory depression.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing cases of respiratory depression, including fatalities, have been reported with the use of promethazine in pediatric patients younger than 2 years. A wide range of weight-based doses of promethazine have resulted in respiratory depression in these patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Exercise caution when administering promethazine to pediatric patients 2 years and older. It is recommended that the lowest effective dose of promethazine be used in pediatric patients 2 years and older and that coadministration with other drugs with respiratory-depressant effects be avoided.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Severe tissue injury, including gangrene (injection):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Promethazine can cause severe chemical irritation and damage to tissues regardless of the route of administration. Irritation and damage can result from perivascular extravasation, unintentional intra-arterial injection, and intraneuronal or perineuronal infiltration. Adverse reactions include burning, pain, thrombophlebitis, tissue necrosis, and gangrene. In some cases, surgical intervention, including fasciotomy, skin graft, and/or amputation have been required.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the risks of intravenous (IV) injection, the preferred route of administration of promethazine is deep intramuscular (IM) injection. Subcutaneous injection is contraindicated.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F214081"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Phenadoz [DSC];</li>
<li>Phenergan;</li>
<li>Promethegan</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F214126"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiemetic;</li>
<li>
                        Histamine H<sub>1</sub> Antagonist;</li>
<li>
                        Histamine H<sub>1</sub> Antagonist, First Generation;</li>
<li>
                        Phenothiazine Derivative</li></ul></div>
<div class="block doa drugH1Div" id="F214085"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: Do not</b> administer IV at concentrations &gt;1 mg/mL. IV administration can cause severe tissue damage (eg, necrosis, gangrene) and chemical irritation. If deep IM administration is not possible, can administer IV<b> only after dilution</b> by infusing through an IV catheter inserted in a large vein (not in hand or wrist) and preferably through a central venous catheter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e90da07d-2e0b-4acd-8903-79bfe2dd19c5">Motion sickness</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Motion sickness (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Other therapies may be preferred due to the risk of significant adverse events, including sedation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25502048','lexi-content-ref-22138695','lexi-content-ref-24346808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25502048','lexi-content-ref-22138695','lexi-content-ref-24346808'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, rectal:</b> Initial: 25 mg 30 to 60 minutes before departure; may repeat 8 to 12 hours later. If needed, may administer 25 mg twice daily on subsequent travel days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4b16bbf2-e10d-45bd-aa5c-cfd1bb289b41">Nausea and/or vomiting, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nausea and/or vomiting, acute: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May use short-term (eg, up to 48 to 72 hours) for self-limiting nausea/vomiting (eg, postoperative rescue therapy, acute vertigo) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Furman.2021','lexi-content-ref-32467512']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Furman.2021','lexi-content-ref-32467512'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, rectal:</b> 12.5 to 25 mg every 4 to 6 hours as needed. To avoid intolerable adverse effects, some experts recommend a maximum dose of 50 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Long.2021','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Long.2021','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM (preferred alternative route) or IV</b>
<b>(alternative route):</b>
<b>Note:</b> IV and IM administration is generally avoided due to risk of severe tissue damage and chemical irritation. When parenteral therapy is indicated, other parenteral antiemetics with less risk of tissue injury are preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ASHP.2020','lexi-content-ref-ISMP.2020','lexi-content-ref-ISMP.2024']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ASHP.2020','lexi-content-ref-ISMP.2020','lexi-content-ref-ISMP.2024'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">12.5 to 25 mg IM or IV every 4 to 6 hours as needed (Barrett 2011; Braude 2008; manufacturer's labeling); for postoperative rescue, may administer 6.25 mg IV as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32467512']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32467512'])">Ref</a></span>). To avoid intolerable adverse effects, some experts recommend a maximum dose of 50 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Long.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Long.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8ad4605e-60e2-416f-ab7e-545de22137af">Nausea and vomiting, pregnancy associated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nausea and vomiting, pregnancy associated (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b>
<b>Safety:</b> IV and IM administration is generally avoided due to risk of severe tissue damage and chemical irritation. When parenteral therapy is indicated, other parenteral antiemetics with less risk of tissue injury are preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ASHP.2020','lexi-content-ref-ISMP.2020','lexi-content-ref-ISMP.2024']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ASHP.2020','lexi-content-ref-ISMP.2020','lexi-content-ref-ISMP.2024'])">Ref</a></span>). <b>Use: </b>May use as add-on therapy when symptoms persist following initial pharmacologic treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29266076']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29266076'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Patients without hypovolemia</i></b>
<b>
<i>:</i> Oral, rectal, IM</b> (alternative route): 12.5 to 25 mg every 4 to 6 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29266076']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29266076'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Patients with hypovolemia </b>(alternative agent, alternative route):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Consider for persistent nausea and vomiting in addition to treatment of hypovolemia (eg, IV fluids) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29266076']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29266076'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 12.5 to 25 mg every 4 to 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29266076']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29266076'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4db80c08-f81a-40bd-b2c3-2273779fb2c1">Peripartum management, adjunct to opioids</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peripartum management, adjunct to opioids:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Other parenteral antiemetics with less risk of tissue injury are preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ASHP.2020','lexi-content-ref-ISMP.2020','lexi-content-ref-ISMP.2024']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ASHP.2020','lexi-content-ref-ISMP.2020','lexi-content-ref-ISMP.2024'])">Ref</a></span>). May be used to potentiate opioid analgesia and decrease side effects (eg, nausea and vomiting) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Grant.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Grant.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM</b> (preferred route), <b>IV</b> (alternative route): 25 mg once; may repeat every 4 hours for up to 2 additional doses.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990309"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (only 0.6% of an administered dose excreted in the urine unchanged) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6849764','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6849764','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed (large V<sub>d</sub>): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (large V<sub>d</sub>): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987630"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer’s labeling; use with caution (cholestatic jaundice has been reported with use).</p></div>
<div class="block doe drugH1Div" id="F214086"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F214105"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12735" href="/d/html/12735.html" rel="external">see "Promethazine: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Use with extreme caution and utilize the lowest effective dose to reduce the risk of adverse effects with all routes of administration. Use has generally been replaced by agents that are more effective with fewer adverse events. Due to risk of severe tissue injury, IV and IM administration is generally avoided.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="03fb9bcc-db9c-46fd-92d3-647d7af01df4">Nausea and vomiting</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nausea and vomiting:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Promethazine has been used as an antiemetic for various presenting conditions (eg, postoperative nausea/vomiting, chemotherapy-induced nausea/vomiting, cyclic vomiting syndrome, migraine). In most clinical situations, routine use has been replaced by alternate agents from other therapeutic classes; however, promethazine may be necessary in refractory situations or as rescue therapy; may consider concomitant diphenhydramine to decrease risk of dystonic adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32467512','lexi-content-ref-25328089','lexi-content-ref-30159612','lexi-content-ref-27176905']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32467512','lexi-content-ref-25328089','lexi-content-ref-30159612','lexi-content-ref-27176905'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents: Oral, IM, IV, rectal: Usual range: 0.25 to 0.5 mg/kg/dose every 4 to 6 hours as needed; doses up to 1.1 mg/kg/dose may be necessary in some patients; do not exceed usual adult dose of 6.25 to 25 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32467512','lexi-content-ref-24512575','lexi-content-ref-4471013','lexi-content-ref-Wyllie.2016','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32467512','lexi-content-ref-24512575','lexi-content-ref-4471013','lexi-content-ref-Wyllie.2016','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4ab55327-e92f-42a7-9218-b327af1066bc">Preprocedure sedation, adjunct</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Preprocedure sedation, adjunct:</b> Children ≥2 years and Adolescents: Oral, IM, IV: 0.5 to 1.1 mg/kg once 30 minutes prior to procedure as part of an appropriate combination regimen; maximum dose: 12.5 to 25 mg/dose; manufacturer recommends in combination with a reduced dose of opioid or barbiturate and an appropriate dosage of an atropine-like drug if appropriate; however, other combination regimens have been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10648310','lexi-content-ref-12779109','lexi-content-ref-24445981','lexi-content-ref-30534169','lexi-content-ref-8673189','lexi-content-ref-8839521','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10648310','lexi-content-ref-12779109','lexi-content-ref-24445981','lexi-content-ref-30534169','lexi-content-ref-8673189','lexi-content-ref-8839521','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51154972"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥2 years and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51154973"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥ 2 years and Adolescents: The manufacturer recommends to avoid use in pediatric patients with signs and symptoms of hepatic disease (extrapyramidal symptoms caused by promethazine may be confused with CNS signs of hepatic disease).</p></div>
<div class="block arsc drugH1Div" id="F56407938"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Anticholinergic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Phenothiazines, including promethazine, may cause anticholinergic adverse effects such as <b>blurred vision</b>, <b>confusion</b>, constipation, dry eye, urinary retention, and <b>xerostomia</b>. Promethazine is included in the Beers Criteria of Potentially Inappropriate Medication Use in Older Adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30693946','lexi-content-ref-9262349']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30693946','lexi-content-ref-9262349'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action (ie, muscarinic receptor antagonism) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29061777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29061777'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; occurs within 1 to 2 hours of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27531858']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27531858'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Age ≥65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30693946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30693946'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other anticholinergic agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30693946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30693946'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS depression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Promethazine use has been associated with <b>dizziness</b>, <b>drowsiness</b>, <b>delirium</b>, <b>motor dysfunction </b>(motor sensory instability), and <b>sedated state</b> in adult (including pregnant women) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24791618','lexi-content-ref-28614956','lexi-content-ref-9262349','lexi-content-ref-21880544','lexi-content-ref-23643576','lexi-content-ref-19042969']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24791618','lexi-content-ref-28614956','lexi-content-ref-9262349','lexi-content-ref-21880544','lexi-content-ref-23643576','lexi-content-ref-19042969'])">Ref</a></span>) and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6105502','lexi-content-ref-6020998','lexi-content-ref-6733616','lexi-content-ref-14709767']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6105502','lexi-content-ref-6020998','lexi-content-ref-6733616','lexi-content-ref-14709767'])">Ref</a></span>). Promethazine is included in the Beers Criteria of Potentially Inappropriate Medication Use in Older Adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30693946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30693946'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; may occur within 30 minutes of ingestion and up to 24 hours after cessation. A delay in cognitive reaction time may be observed within 1 hour of ingestion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24791618','lexi-content-ref-18534808','lexi-content-ref-21880544','lexi-content-ref-23643576']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24791618','lexi-content-ref-18534808','lexi-content-ref-21880544','lexi-content-ref-23643576'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• In overdose, ingestion of &gt;250 mg increases risk for delirium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19042969']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19042969'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Pediatric patients and older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30693946','lexi-content-ref-14709767']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30693946','lexi-content-ref-14709767'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other CNS depressants (eg, alcohol, opioids) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19042969','lexi-content-ref-25822213']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19042969','lexi-content-ref-25822213'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Extrapyramidal symptoms</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Extrapyramidal reactions</b> (EPS), including akathisia, acute dystonia, drug-induced parkinsonism, and tardive dyskinesia, have occurred with the use of promethazine and other dopamine receptor antagonist neuroleptic agents in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28614956','lexi-content-ref-18534808','lexi-content-ref-15972879','lexi-content-ref-6627044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28614956','lexi-content-ref-18534808','lexi-content-ref-15972879','lexi-content-ref-6627044'])">Ref</a></span>). Symptoms of EPS may be confused with other conditions, such as Reye syndrome or other encephalopathy. Acute akathisia is typically transient and resolves with drug discontinuation, but delayed akathisia may be permanent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26573884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26573884'])">Ref</a></span>). Resolution of acute dystonia occurs quickly after drug discontinuation and with supportive care (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10473482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10473482'])">Ref</a></span>). Symptoms of drug-induced parkinsonism typically resolve within 7 months of drug discontinuation but may persist for 18 months or longer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26573884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26573884'])">Ref</a></span>). The use of dopamine receptor antagonists, such as promethazine, may unmask undiagnosed idiopathic Parkinson disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27779780']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27779780'])">Ref</a></span>). Tardive dyskinesia may be irreversible; earlier drug discontinuation increases the likelihood of symptom resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26884326','lexi-content-ref-26573884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26884326','lexi-content-ref-26573884'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action (ie, dopamine D<sub>2</sub> receptor antagonism leading to imbalance in dopamine and acetylcholine in the striatum) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27531858']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27531858'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Akathisia: Rapid; usually occurs within the first 72 hours of therapy initiation (data with prochlorperazine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16490647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16490647'])">Ref</a></span>); however, delayed (tardive) akathisia may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26573884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26573884'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Dystonia: Rapid; usually occurs within the first 5 days after therapy initiation or large dose increase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26884326','lexi-content-ref-26573884','lexi-content-ref-31651896']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26884326','lexi-content-ref-26573884','lexi-content-ref-31651896'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Drug-induced parkinsonism: Varied; onset may be delayed from days to weeks, with 50% to 75% of cases occurring within the first month and 90% within the first 3 months of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30027457','lexi-content-ref-26573884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30027457','lexi-content-ref-26573884'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Tardive dyskinesia: Delayed; symptoms usually occur after at least 3 months of therapy and may occur up to 3 months after therapy discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30027457','lexi-content-ref-26573884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30027457','lexi-content-ref-26573884'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i>
<i></i></p>
<p style="text-indent:-2em;margin-left:6em;">• Akathisia</p>
<p style="text-indent:-2em;margin-left:8em;">- Age &lt;18 years (increasing with decreasing age) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31205194']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31205194'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- IV administration (data with prochlorperazine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30993680']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30993680'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Pregnancy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18071091']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18071091'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Dystonia</p>
<p style="text-indent:-2em;margin-left:8em;">- Age &lt;19 years (increasing with decreasing age) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10473482','lexi-content-ref-26573884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10473482','lexi-content-ref-26573884'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10473482','lexi-content-ref-26573884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10473482','lexi-content-ref-26573884'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Use of agents with high dopamine D<sub>2</sub> receptor affinity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10473482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10473482'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- History of acute dystonia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10473482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10473482'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Underweight or normal body weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31205194']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31205194'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Cocaine use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10473482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10473482'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Pediatric: Acute illness associated with dehydration</p>
<p style="text-indent:-2em;margin-left:6em;">• Drug-induced parkinsonism</p>
<p style="text-indent:-2em;margin-left:8em;">- Age &gt;60 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27779780']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27779780'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27779780']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27779780'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Preexisting movement disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27779780']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27779780'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Cigarette smoking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27779780']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27779780'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Genetic variants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27779780']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27779780'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Tardive dyskinesia</p>
<p style="text-indent:-2em;margin-left:8em;">- Higher cumulative doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26573884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26573884'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Longer durations of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26573884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26573884'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Age ≥65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31205194','lexi-content-ref-26573884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31205194','lexi-content-ref-26573884'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26573884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26573884'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26573884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26573884'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neuroleptic malignant syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroleptic malignant syndrome</b> (NMS) has been associated with the use of dopamine receptor antagonist neuroleptics, including promethazine. Recovery generally occurs after drug discontinuation and with supportive care; however, some cases have been fatal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27423483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27423483'])">Ref</a></span>). Cases with promethazine have been reported following single doses, alone or in combination with other medications and has occurred in patients who have previously received promethazine without incident. Resolution onset has occurred 5 to 7 days after diagnosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11284912','lexi-content-ref-15660719']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11284912','lexi-content-ref-15660719'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; idiosyncratic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10548178','lexi-content-ref-11284912']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10548178','lexi-content-ref-11284912'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; has been reported within 1 to 2 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11284912','lexi-content-ref-15660719']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11284912','lexi-content-ref-15660719'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">- Higher doses (suggested risk factor, but development of NMS is not dose-dependent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27423483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27423483'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">- Rapid dose escalation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27423483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27423483'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">- Concurrent use of dopamine antagonists may increase risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28767476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28767476'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">- Use of agents with high D<sub>2</sub> receptor affinity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27423483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27423483'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">- IV administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27423483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27423483'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">- Use of depot formulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27423483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27423483'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">- Genetic polymorphism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12555236']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12555236'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">- Catatonia may increase risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15660719']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15660719'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Orthostatic hypotension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Phenothiazines, including promethazine, may cause <b>orthostatic hypotension</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19042969','lexi-content-ref-21235099']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19042969','lexi-content-ref-21235099'])">Ref</a></span>). Orthostatic hypotension may increase the risk for falls in older patients; this risk may be augmented by the sedative effects of promethazine.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action (ie, alpha<sub>1</sub>-adrenergic receptor blockade and anticholinergic effects) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21235099','lexi-content-ref-29061777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21235099','lexi-content-ref-29061777'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Onset: Rapid; may occur immediately following IV infusion or following excessive doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21235099']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21235099'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">- Age ≥65 years</p>
<p style="text-indent:-2em;margin-left:6em;">- Higher doses</p>
<p style="text-indent:-2em;margin-left:6em;">- Parenteral administration</p>
<p style="text-indent:-2em;margin-left:6em;">- Concurrent use of thiazide diuretics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25822213']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25822213'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">- Mitral insufficiency</p>
<p style="text-indent:-2em;margin-left:6em;">- Pheochromocytoma</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Respiratory depression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Rare but fatal <b>respiratory depression</b> in neonates and children may occur. An FDA black box warning exists for children &lt;2 years of age; however, it may occur in adults, especially patients with compromised respiratory function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15972879','lexi-content-ref-25822213']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15972879','lexi-content-ref-25822213'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown; may be due to sedation secondary to H<sub>1 </sub>antagonism.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; can occur within minutes to hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4028614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4028614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i>
<i></i></p>
<p style="text-indent:-2em;margin-left:6em;">• Age &lt;2 years</p>
<p style="text-indent:-2em;margin-left:6em;">• Excessive doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7700765','lexi-content-ref-25822213']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7700765','lexi-content-ref-25822213'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of medications that cause respiratory depression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15972879','lexi-content-ref-25822213']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15972879','lexi-content-ref-25822213'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with compromised respiratory function (eg, COPD, sleep apnea)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Tissue injury</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Unintentional intraarterial administration and perivascular extravasation have been associated with <b>local tissue necrosis</b> and subsequent hand and digit amputation in case reports (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6017466','lexi-content-ref-16713815','lexi-content-ref-30783330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6017466','lexi-content-ref-16713815','lexi-content-ref-30783330'])">Ref</a></span>). ISMP discourages the use of injectable promethazine (any route) because of the risk of severe tissue damage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ISMP.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ISMP.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; the acidic pH (4 to 5.5) of promethazine induces cellular and tissue necrosis, leading to complications such as inflammation, vasoconstriction, and thrombosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24420913'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; pain during IV infusion can occur during administration. Skin discoloration and tissue necrosis have occurred immediately following injection and up to 2 weeks after administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6017466','lexi-content-ref-16713815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6017466','lexi-content-ref-16713815'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Dehydration may make IV access challenging, increasing the risk for extravasation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19410998','lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19410998','lexi-content-ref-24420913'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concentrations &gt;25 mg/mL and rapid administration (&lt;10 minutes) increase the risk for extravasation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24714850']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24714850'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Intraarterial administration increases the likelihood of necrosis and amputation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19410998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19410998'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• IV placement in small veins (eg, hand and wrist) increases the risk for inadvertent intraarterial administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19410998','lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19410998','lexi-content-ref-24420913'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F214044"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, decreased blood pressure, local thrombophlebitis (injection), localized phlebitis (injection), peripheral vasospasm (injection), venous thrombosis (injection)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermatitis, skin photosensitivity, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Immune thrombocytopenia, leukopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic jaundice, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Abscess at injection site, erythema at injection site, swelling at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal sensory symptoms (injection), ataxia, catatonia, disorientation, euphoria, excitement, fatigue, hysteria, insomnia, lassitude, nervousness, paralysis (injection), sedated state, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, diplopia</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea, asthma, nasal congestion</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Increased blood pressure (Tsay 2015), orthostatic hypotension (Shi 2011), tachycardia (Tsay 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatological: Gangrene of skin and/or other subcutaneous tissues (injection) (Keene 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Xerostomia (Brown 1997)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Burning sensation at injection site (Keene 2006), local tissue necrosis (injection) (Keene 2006), pain at injection site (Keene 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (Tsay 2015), confusion (Tsay 2015), delirium (Page 2009), dizziness (Brown 1997), drowsiness (Naicker 2013), extrapyramidal reaction (Musco 2019), hallucination (Tsay 2015), hyperexcitability, motor dysfunction (Kavanagh 2012), neuroleptic malignant syndrome (Mendhekar 2005), nightmares, slurred speech (Tsay 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Respiratory depression (Tsay 2015)</p></div>
<div class="block coi drugH1Div" id="F214059"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity or idiosyncratic reaction to promethazine, other phenothiazines, or any component of the formulation; coma; treatment of lower respiratory tract symptoms, including asthma; children &lt;2 years of age; intra-arterial or subcutaneous administration; IV administration at concentrations &gt;1 mg/mL (FDA Safety Communication 2023).</p></div>
<div class="block war drugH1Div" id="F214041"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Altered cardiac conduction: May alter cardiac conduction (life-threatening arrhythmias have occurred with therapeutic doses of phenothiazines).</p>
<p style="text-indent:-2em;margin-left:4em;">• Photosensitivity: May cause photosensitivity; avoid prolonged sun exposure.</p>
<p style="text-indent:-2em;margin-left:4em;">• Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Use with caution in patients with bone marrow suppression; leukopenia and agranulocytosis have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI motility: Use with caution in patients with decreased GI motility or pyloroduodenal obstruction as anticholinergic effects may exacerbate underlying condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Glaucoma: Use with caution in patients with narrow-angle glaucoma; condition may be exacerbated by cholinergic blockade.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; cholestatic jaundice has been reported with use. Avoid use in pediatric patients with signs and symptoms of hepatic disease (extrapyramidal symptoms caused by promethazine may be confused with CNS signs of hepatic disease).</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use with caution in patients with myasthenia gravis; condition may be exacerbated by cholinergic blockade.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ophthalmic conditions: Use with caution in patients with certain ophthalmic conditions (eg, narrow angle glaucoma, visual problems) as anticholinergic effects may exacerbate underlying condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Parkinson disease: Use with caution in patients with Parkinson disease; may have increased risk of tardive dyskinesia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Avoid use in patients with compromised respiratory function or in patients at risk for respiratory failure (eg, COPD, sleep apnea).</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.</p>
<p style="text-indent:-2em;margin-left:4em;">• Urinary tract conditions: Use with caution in patients with urinary retention, benign prostatic hyperplasia (BPH), or bladder neck obstruction, as anticholinergic effects may exacerbate underlying condition.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: <b></b>Antiemetics are not recommended for the treatment of uncomplicated vomiting in pediatric patients; limit use to prolonged vomiting of known etiology. Avoid use in children who may have Reye syndrome or hepatic disease as adverse reactions caused by promethazine may be confused with signs of primary disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP 1997; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ethanol: Oral solution contains 7% ethyl alcohol.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sodium metabisulfite: Injection may contain sodium metabisulfite; may cause allergic reaction.</p></div>
<div class="block foc drugH1Div" id="F214053"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Phenergan: 50 mg/mL (1 mL) [contains edetate (edta) disodium, phenol, sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Phenergan: 25 mg/mL (1 mL) [pyrogen free; contains edetate (edta) disodium, phenol, sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg/mL (1 mL); 50 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 6.25 mg/5 mL (120 mL, 473 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suppository, Rectal, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Phenadoz: 12.5 mg (12 ea [DSC]); 25 mg (12 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Promethegan: 12.5 mg (1 ea, 12 ea); 25 mg (12 ea); 50 mg (1 ea, 12 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 12.5 mg (1 ea, 12 ea); 25 mg (1 ea, 12 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Syrup, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 6.25 mg/5 mL (473 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 12.5 mg, 25 mg, 50 mg</p></div>
<div class="block geq drugH1Div" id="F214037"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F214061"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Phenergan Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg/mL (per mL): $4.04</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/mL (per mL): $5.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Promethazine HCl Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg/mL (per mL): $2.09 - $2.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/mL (per mL): $3.02 - $4.62</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suppository</b> (Promethazine HCl Rectal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg (per each): $15.93 - $17.71</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $15.93 - $17.71</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suppository</b> (Promethegan Rectal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg (per each): $17.71</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $17.71</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $35.77</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Syrup</b> (Promethazine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6.25 mg/5 mL (per mL): $0.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Promethazine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg (per each): $0.49</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.10 - $0.51</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $0.42 - $0.78</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F214056"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with food, water, or milk to decrease GI distress. Measure and administer prescribed dose of oral solution using dosing syringe, dosing spoon, or dosing cup.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral:</b> The Institute for Safe Medication Practices does not recommend the use of injectable promethazine (any route) due to the risk of severe tissue damage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ISMP.2020','lexi-content-ref-ISMP.2024']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ISMP.2020','lexi-content-ref-ISMP.2024'])">Ref</a></span>). <b>Do not</b> administer IV at concentrations &gt;1 mg/mL; may cause severe tissue damage (eg, necrosis, gangrene) and chemical irritation. Not for SUBQ administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> Administer as a deep IM injection.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Administer IV <b>only</b> if IM injection not possible; dilution is required for IV administration; infuse through an IV catheter inserted in a large vein (not in hand or wrist) and preferably through a central venous catheter. Due to risk of severe tissue damage, dilute to a concentration ≤1 mg/mL and infuse over 20 to 40 minutes. Maximum rate of infusion: 2.5 mL/minute if diluted in 50 mL or 5 mL/minute if diluted in 100 mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1','lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1','lexi-content-ref-24420913'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. Discontinue immediately if burning or pain occurs with administration; evaluate for inadvertent arterial injection or extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately; leave cannula/needle in place temporarily but do <b>NOT</b> flush the line; gently aspirate extravasated solution, then remove needle/cannula; elevate extremity. Information conflicts regarding the use of dry warm<b> or</b> dry cold compresses. May consider hyaluronidase antidote for refractory cases in addition to supportive management (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32341081','lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32341081','lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hyaluronidase:</i>
<b>Intradermal or SUBQ:</b> Inject a total of 1 mL (15 units/mL) as five separate 0.2 mL injections (using a tuberculin syringe) around the site of extravasation; if IV catheter remains in place, administer IV through the infiltrated catheter; may repeat in 30 to 60 minutes if no resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52613694"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Measure and administer prescribed dose of oral solution using dosing syringe, dosing spoon, or dosing cup.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> The Institute for Safe Medication Practices recommends against the use of injectable promethazine (any route) due to the risk of severe tissue damage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ISMP.2020','lexi-content-ref-ISMP.2024']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ISMP.2020','lexi-content-ref-ISMP.2024'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Administer as a deep IM injection.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: IV administration should be avoided due to risk for severe tissue damage. If used, promethazine should be administered diluted at a concentration ≤1 mg/mL and infused over 20 to 40 minutes at a maximum rate of 1.25 mL/minute. Administer through an IV catheter in a large bore vein (not in hand or wrist) or via a running IV line at port farthest from patient's vein; central venous catheter is preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1','lexi-content-ref-ISMP.2','lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1','lexi-content-ref-ISMP.2','lexi-content-ref-24420913'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">SUBQ: <b>Do not administer by</b> SUBQ injection; may result in tissue necrosis.</p>
<p style="text-indent:-2em;margin-left:4em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. Discontinue immediately if burning or pain occurs with administration; evaluate for inadvertent arterial injection or extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Information varies regarding the use of dry warm <b>or</b> dry cold compresses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15192356','lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15192356','lexi-content-ref-24420913'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F214055"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Motion sickness:</b> Prophylaxis and treatment of motion sickness.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Nausea and/or vomiting, acute:</b> Prevention and control of nausea and/or vomiting.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peripartum management, adjunct to opioids: </b>May be used to potentiate opioid analgesia.</p></div>
<div class="block off-label drugH1Div" id="F25744619"><span class="drugH1">Use: Off-Label: Adult</span><p>Pregnancy-associated nausea and vomiting</p></div>
<div class="block mst drugH1Div" id="F214135"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Promethazine may be confused with chlorproMAZINE, predniSONE</p>
<p style="text-indent:-2em;margin-left:4em;">Phenergan may be confused with PHENobarbital, Phrenilin, Theragran</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (injectable formulation) among its list of drugs that have a heightened risk of causing significant patient harm when used. ISMP strongly discourages use of injectable promethazine (any route) and suggests facilities remove from all areas (including pharmacy) and not allow practitioners to order (ISMP 2020; ISMP 2024).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Promethazine, a first-generation antihistamine, is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its potent anticholinergic properties resulting in increased risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity; use should also be avoided due to reduced clearance with advanced age and tolerance associated with use as a hypnotic. Exposure to concurrent anticholinergic drugs also increases risk of falls, delirium, and dementia; consider total anticholinergic burden when conducting medication reviews (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Dopamine antagonists, when used in pediatric patients &lt;18 years of age, are identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list; use should be avoided in infants and used with caution in children and adolescents due to risk of acute dystonia (dyskinesia), and with intravenous administration an increased risk of respiratory depression, extravasation, and death (strong recommendation; moderate quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Sominex: Brand name for promethazine in Great Britain, but also is a brand name for diphenhydrAMINE in the US</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F214122"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2B6 (minor), CYP2D6 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F214046"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the adverse/toxic effect of Promethazine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Systemic): Promethazine may diminish the vasoconstricting effect of EPINEPHrine (Systemic).  Management: Avoid epinephrine and consider norepinephrine or phenylephrine when treating hypotension due to promethazine overdose. Consider alternative vasocontrictors in patients treated with promethazine. This combination may be indicated in anaphylaxis treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: Promethazine may enhance the anticholinergic effect of Haloperidol. Promethazine may enhance the CNS depressant effect of Haloperidol. Promethazine may increase the serum concentration of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the adverse/toxic effect of Promethazine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: May enhance the adverse/toxic effect of Promethazine. Specifically, the risk for extrapyramidal symptoms and excessive sedation may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: Promethazine may diminish the therapeutic effect of Pitolisant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54945774"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Use of promethazine may result in false-negative or false-positive hCG-based pregnancy tests.</p></div>
<div class="block pri drugH1Div" id="F214062"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Promethazine crosses the placenta (Potts 1961).</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following maternal use of promethazine during pregnancy are available (Asker 2005; Bártfai 2008; Etwel 2017; Hansen 2020; Larrimer 2014; Schrager 2023). Platelet aggregation may be inhibited in newborns following maternal use of promethazine within 2 weeks of delivery.</p>
<p style="text-indent:0em;margin-top:2em;">Promethazine is indicated for use during labor for obstetric sedation and may be used alone or as an adjunct to opioid analgesics. Promethazine may be used as adjunctive therapy in the management of nausea and vomiting of pregnancy when the preferred agents do not provide initial symptom improvement or when symptoms persist despite other therapies (ACOG 189 2018).</p></div>
<div class="block brc drugH1Div" id="F14456628"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if promethazine is present in breast milk.</p>
<p style="text-indent:0em;margin-top:2em;">Drowsiness and irritability have been reported in breastfed infants exposed to other antihistamines (Ito 1993).</p>
<p style="text-indent:0em;margin-top:2em;">Antihistamines may decrease maternal serum prolactin concentrations when administered prior to the establishment of lactation. This effect was observed following the injection of promethazine to patients on their first postpartum day prior to the initiation of breastfeeding (Messinis 1985).</p>
<p style="text-indent:0em;margin-top:2em;">Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends a decision be made to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother. Single maternal doses of promethazine may be compatible with breastfeeding; repeated doses should be avoided (WHO 2002). Use of a second-generation antihistamine is preferred when an oral antihistamine is needed in lactating patients. Infants exposed to a first-generation antihistamine via breast milk should be monitored for irritability, jitteriness, or drowsiness (Butler 2014, WHO 2002).</p></div>
<div class="block dic drugH1Div" id="F214063"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Increase dietary intake of riboflavin.</p></div>
<div class="block mop drugH1Div" id="F214051"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Relief of symptoms; mental status and CNS effects (including sedation, akathisia, delirium, extrapyramidal symptoms); signs and symptoms of tissue injury (burning or pain at injection site, phlebitis, edema) with parenteral administration.</p></div>
<div class="block pha drugH1Div" id="F214040"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Phenothiazine derivative; blocks postsynaptic mesolimbic dopaminergic receptors in the brain; exhibits a strong alpha-adrenergic blocking effect and depresses the release of hypothalamic and hypophyseal hormones; competes with histamine for the H<sub>1</sub>-receptor; muscarinic-blocking effect may be responsible for antiemetic activity; reduces stimuli to the brainstem reticular system </p></div>
<div class="block phk drugH1Div" id="F214058"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Oral, IM: ~20 minutes; IV: ~5 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Usually 4 to 6 hours (up to 12 hours)</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Rapid and complete; large first pass effect limits systemic bioavailability (Sharma 2003)</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 13.4 ± 3.6 L/kg (Brunton 2011)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 93% (Brunton 2011)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic; hydroxylation via CYP2D6 and N-demethylation via CYP2B6; significant first-pass effect (Sharma 2003)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: ~25% (Sharma 2003); Rectal: 21.7% to 23.4% (Brunton 2011)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: IM: ~10 hours; IV: 9 to 16 hours; Suppositories, syrup: 16 to 19 hours (range: 4 to 34 hours) (Strenkoski-Nix 2000)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to maximum serum concentration (Brunton 2011): Oral (syrup): 2.8 ± 1.4 hours; Rectal: 8.2 ± 3.4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine, feces as inactive metabolites</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038783"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Avomine | Histaloc | Phenergan | Promantine | Prometin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Fenergan | Prometazina Vannier</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Atosil</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Adiramedica promethazine | Allersoothe | Amcal promethazine | Apohealth promethazine allergy relief | Avomine | Blooms the chemist promethazine 10 allergy relief | Blooms the chemist promethazine 25 allergy relief | Chemists' own antihistamine for allergy relief | Cm promethazine | Fenersoothe | Fenezine | Gold cross antihistamine | Medreich promethazine | Metina promethazine hydrochloride | Noumed promethazine | Nyal + allergy rel | Pharmacy action allerelief | Pharmacy choice promethazine | Pharmacy health promethazine | Phenergan | Phenergan elixir | Priceline pharmacy promethazine | Progan | Promadine | Promethazine | Sandoz fenezal | Terrywhite chemmart promethazine | Trust promezine | Twp promethazine | Wagner health promethazine</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Allergina | Antagon | Avomine | Cural | Emomine | Flumin | Methazine | Mitargan | Phenerex | Phenergan | Promafin | Promarid | Promergan | Promestin | Promet | Promodin | Prozin | Sentogan</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Phenergan | Promethazine</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Fenergan | Pamergan | Profergan | Promeclor | Prometazol</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Phenergan</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Promethazine</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Fenergan</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Phenergan | Promethazin | Prothazin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Atosil | Prothazin</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Prometazin era</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Promethasin | Promethazin | Promethazin neuraxpharm</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Phenergan | Promantine</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Frinova</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Promethazine HCL</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Phenergan</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Phenergan</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Avomine | Phenergan | Promethazine | Promethazine teoclat | Sominex | Travel sickness relief</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Phenergan | Phenergan elixir</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Anvomin | Avomine | Fenamin | Fenazin | Phenergan | Phenoma | Pro amine | Procin | Procodyl | Promegan | Promethazine | Synvomin | Vick promethazine | Xepagan</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Avomine | Hufallerzine | Metagan | Nufapreg | Phenergan | Promergan | Promethazine</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Phenergan</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Promethazin | Prothiazine</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alprom | Avomine | Emin | Fuma plus | Histazine | Largan | Medovin | Methazen | Methazine | Methiz | Norgic | Phena | Phenazine | Phenergan | Phenzee | Promet | Prometh 10 | Promethazine | Promezin | Regan</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Phenergan</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Farganesse</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Histazin | Phenergan</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Avomine</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Astargan | Consaprom | Dawa prom | Histargan | Intamine | Medi prom | Promethazine | Prometin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Himazin | Promethazine</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Avomine | Histaloc | Phenergan | Prometin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Codopalm | Phenergan | Prometal | Promethazine</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Phenergan</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Phenergan</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Phenergan</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Phenergan</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Avomine | Hamizine | Hizine | Metaryl | Phenergan | Proezine | Prome | Promene | Promethazine | Promezine | Prothazine | Prozine | Xepagan | Zoralix</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Alben promethazine | Bleormine | Festmetazine | Jovamine | Kp promethazine elixir | Labzine | Mopson promethazine | Pixogan | Promethazine | Rophegan elixir | Sunymine | Zatrox</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Phenergan | Promethazin neuraxpharm | Promethazine</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Phenergan | Promethazin neuraxpharm</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Aft Allersoothe | Allersoothe | Avomine | Phenergan | Promethazine Winthrop</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Phenergan | Promet</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Avinol | Dematic | Jekazine | M Brozine | Miprozine | Phenergan | Progitz elixir | Promethazine | Promine | Semozen</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Diphergan | Polfergan | Promethazine | Prothazin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Phenadoz | Phenergan | Promethazine | Promethazine HCL</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Fenergan | Prometazina basi</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Fenergan</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Avomine | DBL Promethazine Hydrochloride | Farganesse | Histaloc | Phenergan | Prometin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Romergan</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Histaloc | Histazin | Phenergan | Promantin | Prometin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Lergigan | Prometazin actavis</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Axcel Promethazine | Litagan | Promagen | Promel | Promethazine | Promezine | Prozine | Votazine | Xepagan</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Promethazin | Prothazin</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Histergan</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Avomine | Meta | Phenergan | Procodyl | Promethazine</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Phenergan | Promethazine</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Promethazine | Pyrethia</span>;</li>
<li>
<span class="countryCode">(TZ)</span> <span class="country">Tanzania, United Republic of</span><span class="countrySeparator">: </span><span class="drugName">Phenergan</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Astargan | Intamine | Phenaren | Profil 25 | Promago | Promazine elixir | Promethazine</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Fenergan | Prometazina</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Fenergan</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Avomine | Betamethazine | Brunazine | Daralix | Lenazine | Phenergan | Prohist | Promethazine | Receptozine | Triomethazine</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Histergan | Phenergan | Phenergan elixir | Profil 25 | Promethazine | Promethazine HCL | Tilprome</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30693946">
<a name="30693946"></a>2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2019;67(4):674-694. doi:10.1111/jgs.15767<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/30693946/pubmed" id="30693946" target="_blank">30693946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7977894">
<a name="7977894"></a>Aguilar EJ, Keshavan MS, Martínez-Quiles MD, Hernández J, Gómez-Beneyto M, Schooler NR. Predictors of acute dystonia in first-episode psychotic patients. <i>Am J Psychiatry</i>. 1994;151(12):1819-1821. doi:10.1176/ajp.151.12.1819<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/7977894/pubmed" id="7977894" target="_blank">7977894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29266076">
<a name="29266076"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 189: nausea and vomiting of pregnancy. <i>Obstet Gynecol</i>. 2018;131(1):e15-e30. doi:10.1097/AOG.0000000000002456<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/29266076/pubmed" id="29266076" target="_blank">29266076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29334501">
<a name="29334501"></a>American Society of Anesthesiologists (ASA). Practice guidelines for moderate procedural sedation and analgesia 2018: a report by the American Society of Anesthesiologists Task Force on Moderate Procedural Sedation and Analgesia, the American Association of Oral and Maxillofacial Surgeons, American College of Radiology, American Dental Association, American Society of Dentist Anesthesiologists, and Society of Interventional Radiology. <i>Anesthesiology</i>. 2018;128(3):437-479. doi:10.1097/ALN.0000000000002043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/29334501/pubmed" id="29334501" target="_blank">29334501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.2020">
<a name="ASHP.2020"></a>American Society of Health-System Pharmacists (ASHP). ASHP policy positions, 1982-2020. https://www.ashp.org/-/media/assets/policy-guidelines/docs/browse-by-document-type-policy-positions-1982-2020-with-rationales-pdf.ashx?la=en&amp;hash=617965578BFA6D7F5A17D5185268AE5F5D02CEDD. Published 2020. Accessed February 26, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16328314">
<a name="16328314"></a>Asker C, Norstedt Wikner B, Källén B. Use of antiemetic drugs during pregnancy in Sweden. <i>Eur J Clin Pharmacol</i>. 2005;61(12):899-906. doi:10.1007/s00228-005-0055-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/16328314/pubmed" id="16328314" target="_blank">16328314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10648310">
<a name="10648310"></a>Auden SM, Sobczyk WL, Solinger RE, Goldsmith LJ. Oral ketamine/midazolam is superior to intramuscular meperidine, promethazine, and chlorpromazine for pediatric cardiac catheterization. <i>Anesth Analg</i>. 2000;90(2):299-305.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/10648310/pubmed" id="10648310" target="_blank">10648310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20825792">
<a name="20825792"></a>Barrett TW, DiPersio DM, Jenkins CA, et al. A randomized, placebo-controlled trial of ondansetron, metoclopramide, and promethazine in adults. <i>Am J Emerg Med</i>. 2011;29(3):247-255. doi:10.1016/j.ajem.2009.09.028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/20825792/pubmed" id="20825792" target="_blank">20825792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18272326">
<a name="18272326"></a>Bártfai Z, Kocsis J, Puhó EH, Czeizel AE. A population-based case-control teratologic study of promethazine use during pregnancy. <i>Reprod Toxicol</i>. 2008;25(2):276-285. doi:10.1016/j.reprotox.2007.12.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/18272326/pubmed" id="18272326" target="_blank">18272326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24791618">
<a name="24791618"></a>Baumann-Birkbeck L, Grant GD, Anoopkumar-Dukie S, Kavanagh JJ. Drowsiness and motor responses to consecutive daily doses of promethazine and loratadine. <i>Clin Neurophysiol</i>. 2014;125(12):2390-2396. doi:10.1016/j.clinph.2014.03.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/24791618/pubmed" id="24791618" target="_blank">24791618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1989740">
<a name="1989740"></a>Blanc VF, Ruest P, Milot J, et al, “Antiemetic Prophylaxis With Promethazine or Droperidol in Paediatric Outpatient Strabismus Surgery,” <i>Can J Anaesth</i>, 1991, 38(1):54-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/1989740/pubmed" id="1989740" target="_blank">1989740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28614956">
<a name="28614956"></a>Boelig RC, Barton SJ, Saccone G, Kelly AJ, Edwards SJ, Berghella V. Interventions for treating hyperemesis gravidarum: a Cochrane systematic review and meta-analysis. <i>J Matern Fetal Neonatal Med</i>. 2018;31(18):2492-2505. doi:10.1080/14767058.2017.1342805<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/28614956/pubmed" id="28614956" target="_blank">28614956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25077501">
<a name="25077501"></a>Brainard A, Gresham C. Prevention and treatment of motion sickness. <i>Am Fam Physician</i>. 2014;90(1):41-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/25077501/pubmed" id="25077501" target="_blank">25077501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18304050">
<a name="18304050"></a>Braude D, Crandall C. Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: a randomized, double-blind, noninferiority trial. <i>Acad Emerg Med</i>. 2008;15(3):209-215. doi:10.1111/j.1553-2712.2008.00060.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/18304050/pubmed" id="18304050" target="_blank">18304050</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16490647">
<a name="16490647"></a>Braude D, Soliz T, Crandall C, Hendey G, Andrews J, Weichenthal L. Antiemetics in the ED: a randomized controlled trial comparing 3 common agents. <i>Am J Emerg Med</i>. 2006;24(2):177-182. doi:10.1016/j.ajem.2005.08.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/16490647/pubmed" id="16490647" target="_blank">16490647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9262349">
<a name="9262349"></a>Brown TE, Eckberg DL. Promethazine affects autonomic cardiovascular mechanisms minimally. <i>J Pharmacol Exp Ther</i>. 1997;282(2):839-844.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/9262349/pubmed" id="9262349" target="_blank">9262349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brunton.1">
<a name="Brunton.1"></a>Brunton LL, Chabner BA, Knollman BC, eds. <i>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</i>. 12th ed. New York, NY: McGraw-Hill Medical; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12779109">
<a name="12779109"></a>Bui T, Redden RJ, Murphy S. A comparison study between ketamine and ketamine-promethazine combination for oral sedation in pediatric dental patients. <i>Anesth Prog</i>. 2002;49(1):14-18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/12779109/pubmed" id="12779109" target="_blank">12779109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24528912">
<a name="24528912"></a>Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417. doi:10.1016/j.jaad.2013.09.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/24528912/pubmed" id="24528912" target="_blank">24528912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18534808">
<a name="18534808"></a>Callan JE, Kostic MA, Bachrach EA, Rieg TS. Prochlorperazine vs. promethazine for headache treatment in the emergency department: a randomized controlled trial. <i>J Emerg Med</i>. 2008;35(3):247-253. doi:10.1016/j.jemermed.2007.09.047<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/18534808/pubmed" id="18534808" target="_blank">18534808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27986189">
<a name="27986189"></a>Campbell K, Rowe H, Azzam H, Lane CA. The management of nausea and vomiting of pregnancy. <i>J Obstet Gynaecol Can</i>. 2016;38(12):1127-1137. doi:10.1016/j.jogc.2016.08.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/27986189/pubmed" id="27986189" target="_blank">27986189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25466802">
<a name="25466802"></a>Campbell RL, Li JT, Nicklas RA, et al. Emergency department diagnosis and treatment of anaphylaxis: a practice parameter.<i> Ann Allergy Asthma Immunol</i>. 2014;113(6):599-608.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/25466802/pubmed" id="25466802" target="_blank">25466802</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention. <i>CDC Yellow Book 2020: Health Information for International Travel</i>. Oxford University Press; 2020; Chapter 8. <a href="https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-by-air-land-sea/motion-sickness" target="_blank">https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-by-air-land-sea/motion-sickness</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control and Prevention (CDC). Neonatal deaths associated with use of benzyl alcohol--United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10548178">
<a name="10548178"></a>Chan-Tack KM. Neuroleptic malignant syndrome due to promethazine. <i>South Med J</i>. 1999;92(10):1017-1018. doi:10.1097/00007611-199910000-00015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/10548178/pubmed" id="10548178" target="_blank">10548178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26827847">
<a name="26827847"></a>Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. <i>J Pain</i>. 2016;17(2):131-157. doi:10.1016/j.jpain.2015.12.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/26827847/pubmed" id="26827847" target="_blank">26827847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6105502">
<a name="6105502"></a>Cleghorn G, Bourke G. Physostigmine for promethazine poisoning. <i>Lancet</i>. 1980;2(8190):368-369. doi:10.1016/s0140-6736(80)90366-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/6105502/pubmed" id="6105502" target="_blank">6105502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cote.1">
<a name="Cote.1"></a>Coté CJ, Lerman J, Anderson B, eds. <i>A Practice of Anesthesia for Infants and Children</i>. 6th ed. Elsevier; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30113379">
<a name="30113379"></a>Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. <i>Crit Care Med</i>. 2018;46(9):e825-e873. doi:10.1097/CCM.0000000000003299<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/30113379/pubmed" id="30113379" target="_blank">30113379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11284912">
<a name="11284912"></a>Duggal HS. Neuroleptic malignant syndrome precipitated by promethazine and lorazepam. <i>Aust N Z J Psychiatry</i>. 2001;35(2):250-251. doi:10.1046/j.1440-1614.2001.0884c.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/11284912/pubmed" id="11284912" target="_blank">11284912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32707227">
<a name="32707227"></a>Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. <i>J Allergy Clin Immunol</i>. 2020;146(4):721-767.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/32707227/pubmed" id="32707227" target="_blank">32707227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27878468">
<a name="27878468"></a>Etwel F, Faught LH, Rieder MJ, Koren G. The risk of adverse pregnancy outcome after first trimester exposure to H1 antihistamines: a systematic review and meta-analysis. <i>Drug Saf</i>. 2017;40(2):121-132. doi:10.1007/s40264-016-0479-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/27878468/pubmed" id="27878468" target="_blank">27878468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24445981">
<a name="24445981"></a>Fallah R, Alaei A, Akhavan Karbasi S, Shajari A. Chloral hydrate, chloral hydrate--promethazine and chloral hydrate -hydroxyzine efficacy in electroencephalography sedation. <i>Indian J Pediatr</i>. 2014;81(6):541-546.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/24445981/pubmed" id="24445981" target="_blank">24445981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30993680">
<a name="30993680"></a>Fernando T, Lumanauw DD, Youn S, et al. Buccally absorbed vs intravenous prochlorperazine for treatment of migraines headaches. <i>Acta Neurol Scand</i>. 2019;140(1):72-77. doi:10.1111/ane.13104<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/30993680/pubmed" id="30993680" target="_blank">30993680</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14384015">
<a name="14384015"></a>Fitzgerald JP. The effect of promethazine in nausea and vomiting of pregnancy. <i>N Z Med J</i>. 1955;54(300):215-218.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/14384015/pubmed" id="14384015" target="_blank">14384015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26960036">
<a name="26960036"></a>Flank J, Robinson PD, Holdsworth M, et al. Guideline for the treatment of breakthrough and the prevention of refractory chemotherapy-induced nausea and vomiting in children with cancer. <i>Pediatr Blood Cancer</i>. 2016;63(7):1144-1151.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/26960036/pubmed" id="26960036" target="_blank">26960036</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25328089">
<a name="25328089"></a>Flank J, Thackray J, Nielson D, et al. Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: a retrospective, multi-center review. <i>Pediatr Blood Cancer</i>. 2015;62(3):496-501.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/25328089/pubmed" id="25328089" target="_blank">25328089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19410998">
<a name="19410998"></a>Foret AL, Bozeman AP, Floyd WE 3rd. Necrosis caused by intra-arterial injection of promethazine: case report. <i>J Hand Surg Am</i>. 2009;34(5):919-923. doi:10.1016/j.jhsa.2009.01.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/19410998/pubmed" id="19410998" target="_blank">19410998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Furman.2021">
<a name="Furman.2021"></a>Furman JM, Barton JJS. Treatment of vertigo. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 28, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32467512">
<a name="32467512"></a>Gan TJ, Belani KG, Bergese S, et al. Fourth consensus guidelines for the management of postoperative nausea and vomiting. <i>Anesth Analg</i>. 2020;131(2):411-448. doi:10.1213/ANE.0000000000004833<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/32467512/pubmed" id="32467512" target="_blank">32467512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25502048">
<a name="25502048"></a>Golding JF, Gresty MA. Pathophysiology and treatment of motion sickness. <i>Curr Opin Neurol</i>. 2015;28(1):83-88. doi:10.1097/WCO.0000000000000163<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/25502048/pubmed" id="25502048" target="_blank">25502048</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Grant.2021">
<a name="Grant.2021"></a>Grant GJ. Pharmacologic management of pain during labor and delivery. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 26, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8232489">
<a name="8232489"></a>Grunberg SM and Hesketh PJ, “Control of Chemotherapy-Induced Emesis,” <i>N Engl J Med</i>, 1993, 329(24):1790-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/8232489/pubmed" id="8232489" target="_blank">8232489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6017466">
<a name="6017466"></a>Hager DL, Wilson JN. Gangrene of the hand following intra-arterial injection. <i>Arch Surg</i>. 1967;94(1):86-89. doi:10.1001/archsurg.1967.01330070088018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/6017466/pubmed" id="6017466" target="_blank">6017466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32657014">
<a name="32657014"></a>Hansen C, Desrosiers TA, Wisniewski K, Strickland MJ, Werler MM, Gilboa SM. Use of antihistamine medications during early pregnancy and selected birth defects: The National Birth Defects Prevention Study, 1997-2011. <i>Birth Defects Res</i>. 2020;112(16):1234-1252. doi:10.1002/bdr2.1749<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/32657014/pubmed" id="32657014" target="_blank">32657014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15192356">
<a name="15192356"></a>Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/15192356/pubmed" id="15192356" target="_blank">15192356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.1">
<a name="ISMP.1"></a>Institute for Safe Medication Practices (ISMP). 2018-2019 targeted medication safety best practices for hospitals. https://www.ismp.org/guidelines/best-practices-hospitals. Updated December 4, 2017. Accessed April 3, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.2">
<a name="ISMP.2"></a>Institute for Safe Medication Practices (ISMP). Action needed to prevent serious tissue injury with IV promethazine. https://www.ismp.org/resources/action-needed-prevent-serious-tissue-injury-iv-promethazine. Updated August 10, 2006. Accessed February 18, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.2024">
<a name="ISMP.2024"></a>Institute for Safe Medication Practices (ISMP). ISMP list of high-alert medications in acute care settings. https://www.ismp.org/recommendations/high-alert-medications-acute-list. Updated January 10, 2024. Accessed January 12, 2024.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.2020">
<a name="ISMP.2020"></a>Institute for Safe Medication Practices (ISMP). <i>ISMP Targeted Medication Safety Best Practices for Hospitals</i>; 2020. https://www.ismp.org/guidelines/best-practices-hospitals
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8498418">
<a name="8498418"></a>Ito S, Blajchman A, Stephenson M, et al, "Prospective Follow-Up of Adverse Reactions in Breast-Fed Infants Exposed to Maternal Medication," <i>Am J Obstet Gynecol</i>, 1993, 168(5):1393-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/8498418/pubmed" id="8498418" target="_blank">8498418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21880544">
<a name="21880544"></a>Kavanagh JJ, Grant GD, Anoopkumar-Dukie S. Low dosage promethazine and loratadine negatively affect neuromotor function. <i>Clin Neurophysiol</i>. 2012;123(4):780-786. doi:10.1016/j.clinph.2011.07.046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/21880544/pubmed" id="21880544" target="_blank">21880544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16713815">
<a name="16713815"></a>Keene JR, Buckley KM, Small S, Geldzahler G. Accidental intra-arterial injection: a case report, new treatment modalities, and a review of the literature. <i>J Oral Maxillofac Surg</i>. 2006;64(6):965-968. doi:10.1016/j.joms.2005.11.036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/16713815/pubmed" id="16713815" target="_blank">16713815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30159612">
<a name="30159612"></a>Kovacic K, Sood M, Venkatesan T. Cyclic vomiting syndrome in children and adults: what is new in 2018? <i>Curr Gastroenterol Rep</i>. 2018;20(10):46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/30159612/pubmed" id="30159612" target="_blank">30159612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9334501">
<a name="9334501"></a>Kressin M. Ultrastructure of the zymogenic-cell lineage in abomasal mucosa of adult cattle. <i>Anat Histol Embryol</i>. 1997;26(3):217-222. doi:10.1111/j.1439-0264.1997.tb00129.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/9334501/pubmed" id="9334501" target="_blank">9334501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24412116">
<a name="24412116"></a>Larrimer MB, Dajani NK, Siegel ER, Eswaran H, Newport DJ, Stowe ZN. Antiemetic medications in pregnancy: a prospective investigation of obstetric and neurobehavioral outcomes. <i>Am J Obstet Gynecol</i>. 2014;210(3):270.e1-7. doi:10.1016/j.ajog.2014.01.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/24412116/pubmed" id="24412116" target="_blank">24412116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26884326">
<a name="26884326"></a>Lau Moon Lin M, Robinson PD, Flank J, Sung L, Dupuis LL. The safety of prochlorperazine in children: a systematic review and meta-analysis. <i>Drug Saf</i>. 2016;39(6):509-516. doi:10.1007/s40264-016-0398-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/26884326/pubmed" id="26884326" target="_blank">26884326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24714850">
<a name="24714850"></a>Le A, Patel S. Extravasation of noncytotoxic drugs: a review of the literature. <i>Ann Pharmacother</i>. 2014;48(7):870-886. doi:10.1177/1060028014527820<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/24714850/pubmed" id="24714850" target="_blank">24714850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6020998">
<a name="6020998"></a>Leak D, Carroll D. Promethazine poisoning: clinical and electroencephalographic observations. <i>Br Med J</i>. 1967;2(5543):31-32. doi:10.1136/bmj.2.5543.31<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/6020998/pubmed" id="6020998" target="_blank">6020998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16018227">
<a name="16018227"></a>Lewis DW, Yonker M, Winner P, Sowell M. The treatment of pediatric migraine. <i>Pediatr Ann</i>. 2005;34(6):448-460.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/16018227/pubmed" id="16018227" target="_blank">16018227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Long.2021">
<a name="Long.2021"></a>Longstreth GF, Hesketh PJ. Characteristics of antiemetic drugs. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 26, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30783330">
<a name="30783330"></a>Mahajan SS, Tandon VR, Sarin R, Roshi, Gupta AK, Kohli A. Digital gangrene induced by inadvertent intra-arterial cocktail injection of anesthetic agents such as pentazocine, promethazine, and atropine: A serious adverse drug experience. <i>Indian J Pharmacol</i>. 2018;50(6):354-357. doi:10.4103/ijp.IJP_131_18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/30783330/pubmed" id="30783330" target="_blank">30783330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36754">
<a name="36754"></a>McGee JL and Alexander MR, “Phenothiazine Analgesia - Fact or Fantasy?” <i>Am J Hosp Pharm</i>, 1979, 36(5):633-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/36754/pubmed" id="36754" target="_blank">36754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17149959">
<a name="17149959"></a>Melanson SE, Lee-Lewandrowski E, Griggs DA, et al, “Reduced Interference by Phenothiazines in Amphetamine Drug of Abuse Immunoassays,” <i>Arch Pathol Lab Med</i>, 2006, 130(12):1834-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/17149959/pubmed" id="17149959" target="_blank">17149959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15660719">
<a name="15660719"></a>Mendhekar DN, Andrade C. Neuroleptic malignant syndrome with promethazine. <i>Aust N Z J Psychiatry</i>. 2005;39(1-2):113-114. doi:10.1111/j.1440-1614.2005.01524.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/15660719/pubmed" id="15660719" target="_blank">15660719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3928731">
<a name="3928731"></a>Messinis IE, Souvatzoglou A, Fais N, Lolis D. Histamine H1 receptor participation in the control of prolactin secretion in postpartum. <i>J Endocrinol Invest</i>. 1985;8(2):143-146. doi:10.1007/BF03350670.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/3928731/pubmed" id="3928731" target="_blank">3928731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12555236">
<a name="12555236"></a>Mihara K, Kondo T, Suzuki A, et al. Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome. <i>Am J Med Genet B Neuropsychiatr Genet</i>. 2003;117B(1):57-60. doi:10.1002/ajmg.b.10025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/12555236/pubmed" id="12555236" target="_blank">12555236</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30534169">
<a name="30534169"></a>Mozafar S, Bargrizan M, Golpayegani MV, Shayeghi S, Ahmadi R. Comparison of nitrous oxide/midazolam and nitrous oxide/promethazine for pediatric dental sedation: A randomized, cross-over, clinical trial. <i>Dent Res J (Isfahan)</i>. 2018;15(6):411-419.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/30534169/pubmed" id="30534169" target="_blank">30534169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22138695">
<a name="22138695"></a>Murdin L, Golding J, Bronstein A. Managing motion sickness. <i>BMJ</i>. 2011;343:d7430. doi:10.1136/bmj.d7430<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/22138695/pubmed" id="22138695" target="_blank">22138695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31205194">
<a name="31205194"></a>Musco S, Ruekert L, Myers J, Anderson D, Welling M, Cunningham EA. Characteristics of patients experiencing extrapyramidal symptoms or other movement disorders related to dopamine receptor blocking agent therapy. <i>J Clin Psychopharmacol</i>. 2019;39(4):336-343. doi:10.1097/JCP.0000000000001061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/31205194/pubmed" id="31205194" target="_blank">31205194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4028614">
<a name="4028614"></a>Nahata MC, Clotz MA, Krogg EA. Adverse effects of meperidine, promethazine, and chlorpromazine for sedation in pediatric patients. <i>Clin Pediatr (Phila)</i>. 1985;24(10):558-560. doi:10.1177/000992288502401002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/4028614/pubmed" id="4028614" target="_blank">4028614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23643576">
<a name="23643576"></a>Naicker P, Anoopkumar-Dukie S, Grant GD, Kavanagh JJ. The effects of antihistamines with varying anticholinergic properties on voluntary and involuntary movement. <i>Clin Neurophysiol</i>. 2013;124(9):1840-1845. doi:10.1016/j.clinph.2013.04.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/23643576/pubmed" id="23643576" target="_blank">23643576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27531858">
<a name="27531858"></a>Naicker P, Anoopkumar-Dukie S, Grant GD, Neumann DL, Kavanagh JJ. Central cholinergic pathway involvement in the regulation of pupil diameter, blink rate and cognitive function. <i>Neuroscience</i>. 2016;334:180-190. doi:10.1016/j.neuroscience.2016.08.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/27531858/pubmed" id="27531858" target="_blank">27531858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19042969">
<a name="19042969"></a>Page CB, Duffull SB, Whyte IM, Isbister GK. Promethazine overdose: clinical effects, predicting delirium and the effect of charcoal. <i>QJM</i>. 2009;102(2):123-131. doi:10.1093/qjmed/hcn153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/19042969/pubmed" id="19042969" target="_blank">19042969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15521025">
<a name="15521025"></a>Parkman HP, Hasler WL, Fisher RS, “American Gastroenterological Association Medical Position Statement: Diagnosis and Treatment of Gastroparesis,” Gastroenterology, 2004, 127(5):1589-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/15521025/pubmed" id="15521025" target="_blank">15521025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8673189">
<a name="8673189"></a>Petrack EM, Marx CM, Wright MS. Intramuscular ketamine is superior to meperidine, promethazine, and chlorpromazine for pediatric emergency department sedation. <i>Arch Pediatr Adolesc Med</i>. 1996;150(7):676-681.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/8673189/pubmed" id="8673189" target="_blank">8673189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Phenergan.1">
<a name="Phenergan.1"></a>Phenergan (promethazine hydrochloride) ampules [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; June 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Phenergan.2">
<a name="Phenergan.2"></a>Phenergan (promethazine hydrochloride) vial [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27423483">
<a name="27423483"></a>Pileggi DJ, Cook AM. Neuroleptic malignant syndrome. <i>Ann Pharmacother</i>. 2016;50(11):973-981. doi:10.1177/1060028016657553<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/27423483/pubmed" id="27423483" target="_blank">27423483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13737524">
<a name="13737524"></a>Potts CR and Ullery JC, "Maternal and Fetal Effects of Obstetric Analgesia. Intravenous Use of Promethazine and Meperidine," <i>Am J Obstet Gynecol</i>, 1961, 81:1253-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/13737524/pubmed" id="13737524" target="_blank">13737524</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Promethazine hydrochloride oral solution [prescribing information]. Greenville, SC: Pharmaceutical Associates Inc; July 2020.</div>
</li>
<li>
<div class="reference">
                  Promethazine hydrochloride tablets [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals; September 2021.</div>
</li>
<li>
<div class="reference">
                  Promethegan 12.5 mg and 25 mg (promethazine hydrochloride) suppositories [prescribing information]. South Plainfield, NJ: Cosette Pharmaceuticals; March 2020.</div>
</li>
<li>
<div class="reference">
                  Promethegan 50 mg (promethazine hydrochloride) suppositories [prescribing information]. South Plainfield, NJ: Cosette Pharmaceuticals; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7700765">
<a name="7700765"></a>Reappraisal of lytic cocktail/demerol, phenergan, and thorazine (DPT) for the sedation of children. American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1995;95(4):598-602.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/7700765/pubmed" id="7700765" target="_blank">7700765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420913">
<a name="24420913"></a>Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632. doi:10.1002/phar.1396<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/24420913/pubmed" id="24420913" target="_blank">24420913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-RCOG.2016">
<a name="RCOG.2016"></a>Royal College of Obstetricians and Gynaecologists (RCOG). The management of nausea and vomiting of pregnancy and hyperemesis gravidarum. Green-top Guideline No. 69. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg69/. Published June 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27779780">
<a name="27779780"></a>Savica R, Grossardt BR, Bower JH, Ahlskog JE, Mielke MM, Rocca WA. Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study. <i>Mov Disord</i>. 2017;32(2):227-234. doi:10.1002/mds.26839<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/27779780/pubmed" id="27779780" target="_blank">27779780</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36168701">
<a name="36168701"></a>Schrager NL, Parker SE, Werler MM; for the National Birth Defects Prevention Study. The association of nausea and vomiting of pregnancy, its treatments, and select birth defects: findings from the National Birth Defect Prevention Study. <i>Birth Defects Res</i>. 2023;115(3):275-289. doi:10.1002/bdr2.2096<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/36168701/pubmed" id="36168701" target="_blank">36168701</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28767476">
<a name="28767476"></a>Schreiner NM, Windham S, Barker A. Atypical neuroleptic malignant syndrome: diagnosis and proposal for an expanded treatment algorithm: a case report. <i>A A Case Rep</i>. 2017;9(12):339-343. doi:10.1213/XAA.0000000000000610<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/28767476/pubmed" id="28767476" target="_blank">28767476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8839521">
<a name="8839521"></a>Schutzman SA, Liebelt E, Wisk M, Burg J. Comparison of oral transmucosal fentanyl citrate and intramuscular meperidine, promethazine, and chlorpromazine for conscious sedation of children undergoing laceration repair. <i>Ann Emerg Med</i>. 1996;28(4):385-390.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/8839521/pubmed" id="8839521" target="_blank">8839521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32001253">
<a name="32001253"></a>Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis-a 2020 practice parameter update, systematic review, and grading of recommendations, assessment, development and evaluation (GRADE) analysis. <i>J Allergy Clin Immunol</i>. 2020;145(4):1082-1123. doi:10.1016/j.jaci.2020.01.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/32001253/pubmed" id="32001253" target="_blank">32001253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12678691">
<a name="12678691"></a>Sharma A and Hamelin BA, "Classic Histamine H1 Receptor Antagonists: A Critical Review of Their Metabolic and Pharmacokinetic Fate from a Bird's Eye View," <i>Curr Drug Metab</i>, 2003, 4(2):105-29.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/12678691/pubmed" id="12678691" target="_blank">12678691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6733616">
<a name="6733616"></a>Shawn DH, McGuigan MA. Poisoning from dermal absorption of promethazine. <i>Can Med Assoc J</i>. 1984;130(11):1460-1461.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/6733616/pubmed" id="6733616" target="_blank">6733616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27176905">
<a name="27176905"></a>Sheridan DC, Laurie A, Pacheco S, et al. Relative effectiveness of dopamine antagonists for pediatric migraine in the emergency department. <i>Pediatr Emerg Care</i>. 2018;34(3):165-168.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/27176905/pubmed" id="27176905" target="_blank">27176905</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24512575">
<a name="24512575"></a>Sheridan DC, Spiro DM, Meckler GD. Pediatric migraine: abortive management in the emergency department. <i>Headache</i>. 2014;54(2):235-245.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/24512575/pubmed" id="24512575" target="_blank">24512575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21235099">
<a name="21235099"></a>Shi SJ, Platts SH, Ziegler MG, Meck JV. Effects of promethazine and midodrine on orthostatic tolerance. <i>Aviat Space Environ Med</i>. 2011;82(1):9-12. doi:10.3357/asem.2888.2011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/21235099/pubmed" id="21235099" target="_blank">21235099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26525001">
<a name="26525001"></a>Simons FE, Ebisawa M, Sanchez-Borges M, et al. 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. <i>World Allergy Organ J</i>. 2015;8(1):32. doi: 10.1186/s40413-015-0080-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/26525001/pubmed" id="26525001" target="_blank">26525001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4471013">
<a name="4471013"></a>Smith BL, Manford ML. Postoperative vomiting after paediatric adenotonsillectomy. A survey of incidence following differing pre- and postoperative drugs. <i>Br J Anaesth</i>. 1974;46(5):373-378.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/4471013/pubmed" id="4471013" target="_blank">4471013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32341081">
<a name="32341081"></a>Smolders EJ, Benoist GE, Smit CCH, Ter Horst P. An update on extravasation: basic knowledge for clinical pharmacists. <i>Eur J Hosp Pharm</i>. 2020;28(3):165–7. doi:10.1136/ejhpharm-2019-002152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/32341081/pubmed" id="32341081" target="_blank">32341081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15972879">
<a name="15972879"></a>Starke PR, Weaver J, Chowdhury BA. Boxed warning added to promethazine labeling for pediatric use. <i>N Engl J Med</i>. 2005;352(25):2653. doi:10.1056/NEJM200506233522522<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/15972879/pubmed" id="15972879" target="_blank">15972879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy</i>. 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10965395">
<a name="10965395"></a>Strenkoski-Nix LC, Ermer J, DeCleene S, et al, “Pharmacokinetics of Promethazine Hydrochloride After Administration of Rectal Suppositories and Oral Syrup to Healthy Subjects,” <i>Am J Health Syst Pharm</i>, 2000, 57(16):1499-505.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/10965395/pubmed" id="10965395" target="_blank">10965395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20410771">
<a name="20410771"></a>Tan PC, Khine PP, Vallikkannu N, Omar SZ. Promethazine compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial. <i>Obstet Gynecol</i>. 2010;115(5):975-981. doi:10.1097/AOG.0b013e3181d99290<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/20410771/pubmed" id="20410771" target="_blank">20410771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9118814">
<a name="9118814"></a>Tavorath R and Hesketh PJ, “Drug Treatment of Chemotherapy-Induced Delayed Emesis,” <i>Drugs</i>, 1996, 52(5):639-48.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/9118814/pubmed" id="9118814" target="_blank">9118814</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6849764">
<a name="6849764"></a>Taylor G, Houston JB, Shaffer J, et al, “Pharmacokinetics of Promethazine and Its Sulphoxide Metabolite After Intravenous and Oral Administration To Man,” <i>Br J Clin Pharmacol</i>, 1983, 15(3):287-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/6849764/pubmed" id="6849764" target="_blank">6849764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14709767">
<a name="14709767"></a>Timnak C, Gleason O. Promethazine-induced psychosis in a 16-year-old girl. <i>Psychosomatics</i>. 2004;45(1):89-90. doi:10.1176/appi.psy.45.1.89<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/14709767/pubmed" id="14709767" target="_blank">14709767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2190193">
<a name="2190193"></a>Tortorice PV and O'Connell MB, “Management of Chemotherapy-Induced Nausea and Vomiting,” <i>Pharmacotherapy</i>, 1990, 10(2):129-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/2190193/pubmed" id="2190193" target="_blank">2190193</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25822213">
<a name="25822213"></a>Tsay ME, Procopio G, Anderson BD, Klein-Schwartz W. Abuse and intentional misuse of promethazine reported to US poison centers: 2002 to 2012. <i>J Addict Med</i>. 2015;9(3):233-237. doi:10.1097/ADM.0000000000000124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/25822213/pubmed" id="25822213" target="_blank">25822213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration (FDA). FDA drug safety communication: FDA requires updates to labeling for promethazine hydrochloride injection products. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-updates-labeling-promethazine-hydrochloride-injection-products" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-updates-labeling-promethazine-hydrochloride-injection-products</a>. Updated December 27, 2023. Accessed January 12, 2024.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10473482">
<a name="10473482"></a>van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. <i>BMJ</i>. 1999;319(7210):623-626. doi:10.1136/bmj.319.7210.623<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/10473482/pubmed" id="10473482" target="_blank">10473482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29061777">
<a name="29061777"></a>Varga B, Csonka Á, Csonka A, Molnár J, Amaral L, Spengler G. Possible biological and clinical applications of phenothiazines. <i>Anticancer Res</i>. 2017;37(11):5983-5993. doi:10.21873/anticanres.12045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/29061777/pubmed" id="29061777" target="_blank">29061777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30027457">
<a name="30027457"></a>Ward KM, Citrome L. Antipsychotic-related movement disorders: drug-induced Parkinsonism vs. tardive dyskinesia-key differences in pathophysiology and clinical management. <i>Neurol Ther</i>. 2018;7(2):233-248. doi:10.1007/s40120-018-0105-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/30027457/pubmed" id="30027457" target="_blank">30027457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24346808">
<a name="24346808"></a>Weerts AP, Pattyn N, Van de Heyning PH, Wuyts FL. Evaluation of the effects of anti-motion sickness drugs on subjective sleepiness and cognitive performance of healthy males. <i>J Psychopharmacol</i>. 2014;28(7):655-664. doi:10.1177/0269881113516201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/24346808/pubmed" id="24346808" target="_blank">24346808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26573884">
<a name="26573884"></a>Wijemanne S, Jankovic J, Evans RW. Movement disorders from the use of metoclopramide and other antiemetics in the treatment of migraine. <i>Headache</i>. 2016;56(1):153-161. doi:10.1111/head.12712<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/26573884/pubmed" id="26573884" target="_blank">26573884</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at https://apps.who.int/iris/handle/10665/62435
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18071091">
<a name="18071091"></a>Wright MT. Antiemetics, akathisia, and pregnancy. <i>Psychosomatics</i>. 2007;48(6):461-466. doi:10.1176/appi.psy.48.6.461<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/18071091/pubmed" id="18071091" target="_blank">18071091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wyllie.2016">
<a name="Wyllie.2016"></a>Wyllie R, ed. <i>Pediatric Gastrointestinal and Liver Disease</i>. 5th ed. Elsevier, Inc; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6627044">
<a name="6627044"></a>Yung CY. Case vignettes of movement disorders. <i>Brain Res Bull</i>. 1983;11(2):191-194. doi:10.1016/0361-9230(83)90190-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/6627044/pubmed" id="6627044" target="_blank">6627044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31651896">
<a name="31651896"></a>Zhang R, Lai J, Huang J. Acute onset of orofacial dystonia from promethazine treatment: A case report. <i>Medicine (Baltimore)</i>. 2019;98(43):e17675. doi:10.1097/MD.0000000000017675<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/31651896/pubmed" id="31651896" target="_blank">31651896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34536239">
<a name="34536239"></a>Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. <i>Allergy</i>. 2022;77(3):734-766. doi:10.1111/all.15090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/promethazine-drug-information/abstract-text/34536239/pubmed" id="34536239" target="_blank">34536239</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9820 Version 659.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
